ECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
|
|
- Aron Bryan
- 5 years ago
- Views:
Transcription
1 ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups of staff to whom the document relates: Approved by: Date approved: Next Review date: Netty Wood, Lead Pharmacist, ECN Netwk required guidelines ECN Oncology Pharmacy Group Clinicians within ECN Cancer pharmacy staff within ECN Chemotherapy nursing staff within ECN ECN Chemotherapy Board Version No: 1 Responsibility f review: Lead Pharmacist, Essex Cancer Netwk Page 1 of 8
2 Contents Introduction...3 Definition...3 Contributing Risk Facts...3 Aim of therapy...3 Antiemetic Selection...4 Breakthrough Management...5 Exclusion of other causes...5 Antiemetic Infmation...6 Emetic Potential f Individual Drugs...7 Radiotherapy...8 References:...8 Page 2 of 8
3 Introduction Chemotherapy Induced Nausea and Vomiting (CINV) is one of the most frequently experienced side effects encountered by chemotherapy patients. Patients will often find the symptoms distressing, and develop anxiety about the potential f such symptoms to recur on future cycles of chemotherapy. Modern drug treatment can successfully control CINV f the majity of patients. Scope: These guidelines are intended to suppt health professionals in the management and prevention of chemotherapy and radiotherapy induced nausea and vomiting. They are not intended to address nausea and vomiting in palliative care. This guidance applies to adults only. These guidelines are intended to cover adult solid tumour and haemato-oncology patients receiving chemotherapy within the Essex Cancer Netwk. These guidelines are intended to provide a framewk to suppt clinical practice, they can not cover every clinical situation and good common clinical sense and clinical experience will be required when approaching the management of individual patients. These guidelines have purposefully chosen not to recommend one specific 5HT 3 antagonist. Definition Acute Delayed Anticipaty Breakthrough Refracty N&V experienced during the first 24-hour period immediately after chemotherapy administration N&V that occurs me than 24 hours after chemotherapy and may continue f up to 6 7 days after chemotherapy. N&V that occurs pri to the beginning of a new cycle of chemotherapy. It is either a learned response following CINV on a previous cycle an anxiety response. It is most common after 3 to 4 cycles of chemotherapy with very badly controlled acute delayed symptoms. Development of symptoms (nausea vomiting), despite standard anti-emetic therapy, which require treatment with an additional pharmacological agent Patients who have failed on both standard and rescue medication Contributing Risk Facts Patients with 3 me risk facts should be considered to receive additional cover Po control with pri chemotherapy Female sex Younger age <50 years A low chronic alcohol intake pri histy of. Histy of sickness: pregnancy/travelling/surgery Anxiety Smoking Radiation to gastrointestinal (GI) tract, liver, brain Other medications: Various medications can cause nausea and vomiting such as Anaesthetic Agents, Anti-depressants, Anti-microbials, Anti-fungals, Iron, Levdopa, Carbodopa, NSAIDs. Aim of therapy The aim of antiemetic therapy is to prevent nausea and vomiting. Prophylactic antiemetic treatment should be given pri to chemotherapy, should be given regularly and should continue f at least 48hrs after treatment has finished. PRN antiemetics should always be available, preferably using drugs with a different mode of action to the regular antiemetics and should also be available via a route not dependant on GI absption, such as parenteral, rectal buccal, as this may be compromised in patients experiencing breakthrough nausea and/ vomiting. Optimal emetic control in the acute phase is essential to prevent nausea and vomiting in the delayed phases and to reduce the chances of anticipaty vomiting developing in later cycles of treatment. Page 3 of 8
4 Antiemetic Selection Emetogenic Potential Low Risk of emesis in < 10% Pre Chemotherapy Schedule (f each day of chemotherapy) No routine antiemetics usually necessary. Post Chemotherapy (day after chemotherapy finished) Domperidone 20mg tds prn PO 5/7 Or Metoclopramide 10mg tds prn PO 5/7 Action f Antiemetic Failure If no routine antiemetics taken: 1st line antiemetics f breakthrough. Treat on subsequent courses the same. If routine antiemetics taken: 2nd line antiemetics f breakthrough. Manage subsequent cycles as moderate emetogenic. Moderate Risk of emesis in 10-30% Dexamethasone 8mg PO/IV Dexamethasone 8mg od PO 2/7 ( 8mg od 1/7, 4mg od 1/7) Domperidone 20mg tds PO prn 5/7 Metoclopramide 10mg tds PO prn 5/7 Commence with 2nd line antiemetics f breakthrough. Manage subsequent cycles as high emetogenic. High Risk of emesis in 30-90% Dexamethasone 20mg PO/IV Dexamethasone 8mg od PO 2/7 ( 8mg od 1/7, 4mg od 1/7) Domperidone 20mg tds PO prn 5/7 Metoclopramide 10mg tds PO prn 5/7 Commence with 3rd line anti-emetics f breakthrough. Consider including these as part of take home medication. Manage subsequent cycles as severe emetogenic. Consider Prochlperazine 3mg bd buccal prn 5/7 Severe Risk of emesis in nearly all patients >90% Anticipaty Nausea and Vomiting Dexamethasone 12mg PO/IV Aprepitant 125mg PO, fosapripitant (IV), long acting 5HT 3 antagonist (omit other 5HT 3 antagonist) If nausea and vomiting is well controlled during and after chemotherapy, anticipaty nausea and vomiting is unlikely to occur. Dexamethasone 8mg od PO 3/7 Aprepitant 80mg od PO 2/7 (omit if given long acting 5HT 3 antagonist) Domperidone 20mg tds PO prn 5/7 Metoclopramide 10mg tds PO prn 5/7 Consider Prochlperazine 3mg bd buccal prn 5/7 Commence with 3rd line anti-emetics f breakthrough. Consider including these as part of take home medication. Continuous subcutaneous infusions may be indicated f poly controlled patients. Lazepam 1mg ally, sublingually IV 30 minutes befe chemotherapy is given. Patients may benefit from al lazepam the night befe and/ on the mning of chemotherapy Page 4 of 8
5 Notes: Sht acting 5HT 3 antagonists are interchangeable and choice of drug should be based on cost. Doses should be in line with relevant SPC. Oral antiemetics are as effective as intravenous administration and may be given pri to chemotherapy (at least 30 minutes befe chemotherapy.) Using antiemetics with the same mode of action should be avoided where possible as this increases the risk of side effects as a result of overlapping toxicities. Where steroids are part of the chemotherapy regimen e.g. in lymphomas, it may be appropriate f the antiemetic steroids (e.g. dexamethasone) to be omitted. The risks and benefits of steroids should be considered in patients with co-existing diseases, such as diabetes, and where appropriate should be avoided if possible. Domperidone is recommended in younger patients because of the increased risk of dystonic reactions with metoclopramide. F multi-day regimens, give antiemetics as per Pre Chemotherapy Schedule (f each day of chemotherapy). Breakthrough Management Anti-emetic failure is described as: 4 hours of moderate to severe nausea 2 me episodes of vomiting and/ retching in 24 hours There are 3 key steps f successful management Exclusion of other causes Treatment accding to the cause Planning f the next cycle Table 2: Action f antiemetic failure (Breakthrough Management) 1st line Domperidone 20mg tds PO Or Domperidone 60mg bd PR Metoclopramide 10mg tds PO/IV/SC 2nd line Levomepromazine 6.25mg bd po Or Cyclizine 50mg tds PO/IV/SC Prochlperazine 3mg bd Buccal 3rd line Haloperidol 1mg-3mg tds PO/IV Levomepromazine 6.25mg to 12.5mg bd PO/SC Continuous subcutaneous infusions may be useful f poly controlled emesis +/- Lazepam 1mg PO/IV/SL qds prn Useful where anxiety may be contributing to nausea and vomiting Exclusion of other causes It is easy to assume that nausea and vomiting in a patient who has recently received chemotherapy is the result of their chemotherapy. However there are several other causes of nausea and vomiting many of which will commonly present in cancer patients and should therefe be excluded: Other medications Constipation Bowel Obstruction Anxiety Metabolic Abnmalities (eg Renal Failure) Hyper-calcaemia Peptic Ulcer Disease Radiotherapy Metastases / Raised Intra Cranial Pressure Fluid and electrolyte imbalances (hypercalcaemia, Renal Failure) If another cause is identified this should be crected treated. Page 5 of 8
6 Antiemetic Infmation Please refer to BNF/SPC f me infmation 5HT3 antagonist Aprepitant Cyclizine Dexamethasone Domperidone Haloperidol Levomepromazine Lazepam Metoclopramide Prochlperazine Patients may complain of constipation and headaches. Patients need to be advised accdingly, ie Senna/Milpar to relieve constipation, Paracetamol to relieve headache. If severe substitute alternative 5HT 3 (side effects are class effect and patient may still experience with alternative 5HT 3 ) alternative anti-emetic Significant drug interactions on CYP3A4 and CYP2C9 enzyme systems and drug interactions need to be checked. The maximum recommended dose of Dexamethasone with Aprepitant is 12mg per day. Common side effects include hiccups, dyspepsia, diarrhoea, constipation, asthenia, headache, dizziness. cyclizine should be used with caution in patients with glaucoma, obstructive disease of the gastrointestinal tract, hepatic disease, severe heart failure, epilepsy and in males with possible prostatic hypertrophy. Urticaria, drug rash, drowsiness, headache, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia and audity and visual hallucinations have been repted, particularly when dosage recommendations have been exceeded. Cticosteroids can cause sleep disturbances, hyperactivity and excessive appetite. They also produce glucose-intolerance, use with care in patients with diabetes mellitus. Patients may experience perineal discomft if the drug is given by iv bolus. This is avoided by iv infusion. Domperidone should not be used when stimulation of the gastric motility could be harmful eg gastro-intestinal haemrhage, mechanical obstruction perfation. Domperidone can increase in prolactin levels. Caution in patients with liver disease renal failure, epilepsy, disturbed thyroid function patients with risk facts f cardiac arrhythmias. Haloperidol can interact with some anti-epileptics. Side effects include extra pyramidal symptoms, tardive dyskinesia, cardiac effects, dry mouth and constipation. Avoid in patients with liver dysfunction. Inhibits cytochrome P-450. Common side effects are somnolence, asthenia, dry mouth, hypotension, photosensitivity and skin reactions. Can cause drowsiness and may affect perfmance of skilled tasks (driving) Can rarely cause agitation the development of extra-pyramidal symptoms. These can occur up to 24 hours after a dose and may vary from facial grimacing and dystonic movements to odd feelings in the mouth, restlessness, somnolence and irritability. Treat with procyclidine 10mg iv stat diazepam (diazemuls) 10mg iv stat, discontinue metoclopramide and do not re-use. Particular caution should be exercised when giving metoclopramide to patients under the age of 20 years. Bowel transit time may be reduced and some patients experience diarrhoea. Substitute with cyclizine. Prochlperazine should be avoided in patients with liver renal dysfunction, Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis, prostate hypertrophy. A mild leukopenia occurs in up to 30% of patients on prolonged high dosage Page 6 of 8
7 Emetic Potential f Individual Drugs The individual emetogenicity of chemotherapy agents has been derived from Kris et al American Society of Clinical Oncology Guideline f Antiemetics in Oncology: Update 2006 Combination Chemotherapy When assessing the emetogenicity of combination chemotherapy: 1. Start at Low emesis then a. F each drug with an emetogenic risk >30% increase one level. Do this f all drugs with an emetogenic risk >30% b. F a drug with an emetogenicity 10-30% the emetogenicity should be increased one level c. F a drug with an emetogenicity < 10% no adjustment is necessary. Example: 3 drug combination with 2 drugs high emesis (30% -90% risk) and one low emesis = Severe overall F regimen emetogenicity please see ECN approved list Table 3: Emetic Potential f Individual Drugs Low emesis (<10% incidence) Moderate Emesis (10%-30% incidence) High Emesis (30% to 90% incidence) Severe Emesis (>90% incidence) Alemtuzumab Arsenic Altretamine Busulfan high doses Asparaginase Btezomib Amsacrine Carmustine > 250mg/m2 Bevacizumab Carmustine <100mg/m2 Carboplatin Cisplatin >60mg/m2 Bleomycin Caelyx (liposomal doxubicin) Carmustine >100mg/m2 Cyclophosphamide >1500mg/m2 Busulfan <10mg Cetuximab Cisplatin < 60mg/m2 Capecitabine Cyclophosphamide Cyclophosphamide Dacarbazine <750mg/m2 >750mg/m2 - <1500mg/m2 Cetuximab Cytarabine <900mg/m2 Cytarabine > 900mg/m2 Ifosfamide >3g/m2 Chlambucil Daunubicin <50mg/m2 Dactinomycin Cladrabine Docetaxel Daunubicin > 50mg/m2 Etoposide Doxubicin <60mg/m2 Doxubicin > 60mg/m2 Fludarabine Gemcitabine Epirubicin Fluouracil Methotrexate Estramustine 250mg/m2 -<1000mg/m2 Gefitnib Mitomycin C Idarubicin Gemtuzumab Mitoxantrone Ifosfamide <3g/m2 Hydroxyurea Paclitaxel Irinotecan Imatinib Procarbazine Lomustine Liposomal Daunubicin Temozolomide Melphalan IV >100mg/m2 Liposomal Doxubicin Topotecan Methotrexate >1000mg/m2 Melphalan al Oxaliplatin Mercaptopurine Streptozocin Methotrexate <250mg/m2 Vinelbine Oral Pentostatin Rituximab Thioguanine Trastuzumab Vinblastine Vincristine Vindesine Vinelbine Page 7 of 8
8 Radiotherapy Table 5: Risk associated irradiated area and the recommended antiemetic guideline Risk Level Minimal Irradiated Area Head and neck, extremities, cranium and breast Pre-Radiotherapy Antiemetic 1 hour befe each fraction No routine antiemetics usually necessary, Consider: Domperidone 20mg tds PO Metoclopramide 10mg tds PO Rescue Antiemetic Domperidone 20mg tds PO Metoclopramide 10mg tds PO Where anti-dopamine agent has been used: Low Lower thax region and pelvis Cranium (radiosurgery) and cranospinal Domperidone 20mg tds PO Metoclopramide 10mg tds PO Consider: Where a 5HT 3 has been used: Cyclizine 50mg tds PO/IV/SC Prochlperazine 10mg tds PO Moderate High Upper abdomen hemibody irradiation, upper abdomen, abdominal-pelvic, mantle, craniospinal irradiation, and cranial radiosurgery Total body irradiation (TBI) and Dexamethasone 8mg PO/IV and Levomepromazine 6.25mg to 12.5mg bd PO/SC Haloperidol 1mg-3mg tds PO/IV/SC Levomepromazine 6.25mg to 12.5mg bd PO/SC Metoclopramide 10mg tds prn Continue f 24 hours after fraction References: Hesketh PJ, Kris MG, Grunberg SM et al. Proposal f classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997:15(1); Gralla RJ, Osoba D, Kris MG, et al. Recommendations f the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 1999:17; Gralla RJ, Roila F et al. The 2004 Perugia Antiemetic Consensus Guideline Process: methods, procedures and participants. Suppt Care Cancer (2005) 13: Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology Guideline f Antiemetics in Oncology: Update J Clin Oncol 2006:24(18)ASCO special article. Recommendation f the use of antiemetics: Evidence Based, clinical practice guidelines. J of Clinical Oncology, Vol 17 No 9, 1999: Hesketh, p., Proposal f classifying the acute emetogenicity of cancer chemotherapy. J of Clinical Oncology, Vol 15 No 1, 1997: Stoner. N., Anti-emetic policy f the prophylaxis of chemotherapy induced nausea and vomiting. Churchill Hospital 2003 Protocol (Oncology and Haematology) - Antiemetic Prescription. Addenbrook s NHS trust Perugia International Cancer Conference VII March 2004 updated September 2005 MASCC Page 8 of 8
Guidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationNCCN Clinical Practice Guidelines in Oncology. Antiemesis V Continue.
Clinical in Oncology V.4.2009 Continue www.nccn.g Table of Contents Panel Members *David S. Ettinger, MD/Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Steve Kirkegaard, PharmD Huntsman
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationCLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS
CLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS Procedure reference: Document owner: 2196 Version: V2.1 Robert Duncombe, The Director
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis V Continue.
Clinical in Oncology V.1.2009 Continue www.nccn.g Table of Contents Panel Members *David S. Ettinger, MD/Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Debra K. Armstrong, RN # Vanderbilt-Ingram
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis V Continue.
Clinical in Oncology V.3.2009 Continue www.nccn.g Table of Contents Panel Members *David S. Ettinger, MD/Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Debra K. Armstrong, RN # Vanderbilt-Ingram
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationCLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical and nursing staff working with paediatric oncology patients. 2. The
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationAnti-Emetic Guidelines for Adults Receiving Chemotherapy
Anti-Emetic Guidelines for Adults Receiving Chemotherapy Version 2 Date of Publication: February 2007 Updated February Original Author(s): Sue Robinson Lead Pharmacist Arden Cancer Network Edited & adapted
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationGUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.
Page 1 of 20 Guideline for the management of chemotherapy-induced nausea and vomiting, v2.1.1 GUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. Version: 2.1.0 Ratified by: Date
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationpatient group direction
CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationNausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA
Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea
More informationDocetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer
Docetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer Indication: Neoadjuvant therapy f HER 2 negative high risk and fit Breast Cancer patients, suitable f a taxane containing
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationThames Valley. Grading of Nausea and Vomiting 1,5
Anti-emetic guidelines for the prophylaxis of Chemotherapy and Radiotherapy induced nausea and vomiting in ADULTS (for use by Haematologists and Oncologists) Introduction Chemotherapy Induced Nausea and
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationComplications of the Systemic Treatment of Cancer
Complications of the Systemic Treatment of Cancer An Introduction to Acute Oncology July 2015 Aims and Objectives To be aware of the range of systemic therapies used in modern cancer care To list the potential
More informationAntiemesis. Overview. Clinical Practice Guidelines in Oncology
456 NCCN Clinical Practice Guidelines in Oncology David S. Ettinger, MD; Debra K. Armstrong, RN, OCN; Sally Barbour, PharmD, BCOP, CPP; Michael J. Berger, PharmD, BCOP; Philip J. Bierman, MD; Bob Bradbury,
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT
ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL Doses of opiates must be proptional to current analgesic medication Please refer ALL patients on Methadone Ketamine to SPCT f advice. Patients
More informationEC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer
EC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen EC
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationGastrointestinal Alterations
Gastrointestinal Alterations Nancy Thompson, RN, MS, AOCNS Swedish Cancer Institute Nausea & Vomiting Mucositis Taste Alterations Anorexia / Cachexia GI Alterations The Chinese do not draw any distinction
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationGastrointestinal obstruction Dr Iain Lawrie
Gastrointestinal obstruction Dr Iain Lawrie Consultant and Honorary Clinical Senior Lecturer in Palliative Medicine The Pennine Acute Hospitals NHS Trust / The University of Manchester iain.lawrie@pat.nhs.uk
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationFEC Docetaxel (NEOADJUVANT): Fluorouracil/ Epirubicin/ Cyclophosphamide followed by Docetaxel* in Early Breast Cancer
FEC Docetaxel (NEOADJUVANT): Fluouracil/ Epirubicin/ Cyclophosphamide followed by Docetaxel* in Early Breast Cancer Please, note that Neoadjuvant FEC-Docetaxel has only been approved f use in QEW Trust
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationAcute GI effects of radiotherapy
Acute GI effects of radiotherapy Dr Alex Stewart Hon Senior Lecturer, University of Surrey Clinical Director, St Luke s Cancer Centre, University of Surrey, Guildford Learning Objectives Acute Radiotherapy
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More informationThalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
Outpatient Anti Cancer Treatment Handbook LCV Lomustine, Cisplatin, Vincristine Packer Regimen Repeated every 6 weeks for a maximum of 6 cycles Approved for use in: Medulloblastoma adjuvant therapy Dosage:
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationMATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More information